← All trials
NCT01091675
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2010
- Primary completion
- May 1, 2013
- Completion date
- May 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 58
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Spanish Foundation of RheumatologyLead sponsor
- General de Mostoles HospitalOverall official - principal investigator
- Hospital de Sant Pau i Santa Tecla de TarragonaOverall official - principal investigator
- Corporacion Parc TauliOverall official - principal investigator
- University of BarcelonaOverall official - principal investigator
- Universidad Complutense de MadridOverall official - principal investigator
- Universidad de MurciaOverall official - principal investigator
- Universidad Autonoma de MadridOverall official - principal investigator
- Universidad de CordobaOverall official - principal investigator
- University of SalamancaOverall official - principal investigator
- Autonomous University of MadridOverall official - principal investigator
- Hospital Universitario Central de AsturiasOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.